{"organizations": [], "uuid": "279122ec7ce54dd4c14908fc9f6d431a6595c152", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180502.html", "section_title": "Archive News &amp; Video for Wednesday, 02 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/health-aegerion/judge-sets-swift-schedule-for-assessing-aegerion-victim-claims-idUSL1N1SA02D", "country": "US", "domain_rank": 408, "title": "Judge sets swift schedule for assessing Aegerion victim claims", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.831, "site_type": "news", "published": "2018-05-03T09:31:00.000+03:00", "replies_count": 0, "uuid": "279122ec7ce54dd4c14908fc9f6d431a6595c152"}, "author": "Nate Raymond", "url": "https://www.reuters.com/article/health-aegerion/judge-sets-swift-schedule-for-assessing-aegerion-victim-claims-idUSL1N1SA02D", "ord_in_thread": 0, "title": "Judge sets swift schedule for assessing Aegerion victim claims", "locations": [], "entities": {"persons": [{"name": "aegerion", "sentiment": "none"}, {"name": "marianne bowler", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "boston", "sentiment": "none"}], "organizations": [{"name": "westlaw", "sentiment": "none"}, {"name": "u.s. justice department", "sentiment": "none"}, {"name": "aegerion pharmaceuticals inc", "sentiment": "none"}, {"name": "novelion therapeutics inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "A federal magistrate judge on Wednesday said she wanted to move swiftly in assessing claims by victims seeking a cut of a U.S. Justice Department settlement with Aegerion Pharmaceuticals Inc over its improper marketing of a cholesterol drug.\nU.S. Magistrate Judge Marianne Bowler at a hearing in Boston sought to assess the best path to distributing up to $7.2 million set aside for patients who were harmed after using Juxtapid, a drug produced by Aegerion, a Novelion Therapeutics Inc unit.\nTo read the full story on Westlaw Practitioner Insights, click here: bit.ly/2rjk4Rs\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/", "http://bit.ly/2rjk4Rs"], "published": "2018-05-03T09:31:00.000+03:00", "crawled": "2018-05-03T12:22:36.052+03:00", "highlightTitle": ""}